Resumo

GARCIA SALINAS, R.N. et al. Treatment of psoriatic arthritis with ustekinumab in different clinical scenarios: Real cases and literature review. Rev. argent. reumatolg. [online]. 2016, vol.27, n.3, pp.32-38. ISSN 0327-4411.

The Psoriatic Arthritis (PsA) treatment is based on removing the signs and symptoms in all components of the disease (joint, skin, enthesis, axial). Among the therapeutic options have nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying drugs (DMARs) including methotrexate and leflunomide, and TNF blocker, that demonstrated broad long-term efficacy and good safety profile; and were the only mechanism of action approved for PsA, however in the last year was approved in several countries, the first biological drug with a different mechanism of action, ustekinumab, an inhibitor of the p40 subunit of IL-12 and 23. This review presents a series of 6 clinical cases where we have used this therapeutic option in different scenarios.

Palavras-chave : psoriatic arthritis; treatment; ustekinumab.